产品说明书
Methylthiouracil
 |
同义名 : | 甲硫氧嘧啶 ;MTU |
| CAS号 : | 56-04-2 | |
| 货号 : | A215834 | |
| 分子式 : | C5H6N2OS | |
| 纯度 : | 98% | |
| 分子量 : | 142.18 | |
| MDL号 : | MFCD00006040 | |
| 存储条件： |
粉末 Keep in dark place,Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(351.67 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Human Umbilical Vein Endothelial Cells (HUVECs) are exposed to various concentrations of Methylthiouracil (MTU), ranging from 0 to 20 μM, for six hours following an initial treatment with LPS (100 ng/mL) for four hours. MTU effectively reduces LPS-induced hyperpermeability in these endothelial cells, showing maximal efficacy at concentrations exceeding 5 μM. Additionally, subsequent treatment with MTU at 10 or 20 μM suppresses the formation of LPS-induced paracellular gaps while promoting the development of dense F-actin rings. To evaluate MTU's safety, cellular viability assays are conducted on HUVECs treated with MTU for 24 hours, confirming that MTU up to 20 μM does not compromise cell viability[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
7.03mL 1.41mL 0.70mL |
35.17mL 7.03mL 3.52mL |
70.33mL 14.07mL 7.03mL |
| 参考文献 |
|---|